Health Highlights: Sept. 19, 2013
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Chemotherapy Undertreatment Common in Obese Cancer Patients
Many obese cancer patients receive inadequate doses of chemotherapy and this is one reason why they have higher rates of cancer recurrence and death, experts say.
In order to correct the problem, the American Society of Clinical Oncology has adopted guidelines promoting full, weight-based chemotherapy doses for obese patients, the Associated Press reported.
Doctors should use a patient's size to calculate chemotherapy doses, but often fail to do so with those who are obese, the report said. One reason is concern about how much chemotherapy an obese patient can bear, but research shows that larger people cope with chemotherapy better than smaller people.
Studies suggest that as many as 40 percent of obese cancer patients receive less than 85 percent of the right doses for their size, according to the AP.
The American Society of Clinical Oncology's new advice should be viewed as right-sizing cancer care, said Dr. Gary Lyman, a Duke University oncologist who led the guidelines panel.
"There's little doubt that some degree of undertreatment is contributing to the higher mortality and recurrence rates in obese patients," he told the AP.
There is a problem with obese cancer patients receiving inadequate chemotherapy doses, said Dr. Richard Pazdur, director of the U.S. Food and Drug Administration's office of cancer drugs.
"By minimizing the dose, or capping the dose, we have been undertreating patients," he told the AP.
The issue affects a lot of patients, as 60 percent of Americans are overweight and more than one-third are obese.
Alzheimer's Prevention Study Gets $33 Million Grant
The U.S. government said Wednesday that it has given a $33.2 million grant to a study that will test if a drug can prevent Alzheimer's in people at greatest risk for developing the most common form of the disease.
The grant was awarded to researchers at the Banner Alzheimer's Institute in Phoenix. The clinical trial will focus on the late-onset form of the disease, which affects the vast majority of the 5 million Americans estimated to have Alzheimer's, The New York Times reported.
The study will include people ages 60 to 75 who do not have any symptoms of the disease, but do have two copies of a gene known to greatly increase the risk of developing it.
This is the largest federal grant ever awarded to test a drug specifically designed to prevent Alzheimer's in people without symptoms, said Laurie Ryan, program director for Alzheimer's disease clinical trials at the National Institute on Aging, part of the National Institutes of Health, The Times reported.
The government on Wednesday announced a total of $45 million in grants for Alzheimer's research.
Copyright © 2013 HealthDay. All rights reserved.